Vedise introduce Ozilia for chronic migraine to Italy’s anesthesiologists 

Chordate Medical’s Italian partner Vedise introduces Ozilia for chronic migraine on The ACD congress in Palermo, on June 19-21. The congress gathers around 300 anesthesiologists and neurologists focused on pain treatment. The umbrella organization SIAARTI organizes three themed congresses per year, where in addition to pain (ACD), intensive care and emergency care are also thematic areas. Vedise is a gold sponsor of ACD.

“The interest in Ozilia is noticeable, primarily because this is a group of doctors who routinely engage in therapeutic pain treatment and therefore have extensive experience with medical technology,” says Valter Varano, CEO and owner of Vedise.


For Vedise and Chordate, anesthesiologists are a new target group, in addition to neurology, when it comes to the Italian market.

During the congress, Dr. Charly Gaul, one of the most productive principal investigators in Chordate’s follow-up study PM010, gave a well-attended lecture on his experiences with Ozilia treatment. During the subsequent discussion, a number of interesting questions from the audience were answered.

“It is very gratifying to support Valter and his team in their professional introduction of Ozilia for chronic migraine on the Italian market,” says Anders weilandt, Chordate CEO.

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy